Zimmer Biomet (ZBH) Set to Announce Quarterly Earnings on Thursday

Zimmer Biomet (NYSE:ZBH) will release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Zimmer Biomet to post earnings of $1.88 per share for the quarter. Zimmer Biomet has set its FY24 guidance at $8.00-8.15 EPS and its FY 2024 guidance at 8.000-8.150 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter last year, the company earned $1.88 earnings per share. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $121.17 on Thursday. Zimmer Biomet has a one year low of $102.00 and a one year high of $149.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The business has a fifty day moving average of $126.18 and a two-hundred day moving average of $119.46. The company has a market cap of $24.90 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 2.22 and a beta of 1.01.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Insider Buying and Selling at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ZBH shares. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, February 9th. StockNews.com downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, Truist Financial lifted their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.